Results of the first World Health Organization international collaborative study of detection of Human Papillomavirus DNA.
(2006) In Journal of Clinical Microbiology 44(2). p.571-579- Abstract
- Twenty-nine laboratories in 12 countries participated in a study to assess the performance of various human
papillomavirus (HPV) detection assays through the use of a recombinant HPV DNA standard reagent panel.
The panel was designed by a group of HPV experts, and samples were prepared and distributed by the World
Health Organization International Laboratory for Standards and Biologicals in The Netherlands. Each panel
consisted of 24 coded samples including a dilution series for HPV types 16 and 18, alone or in combination with
five other high-risk (HR) HPV types including HPV types 31, 33, 35, 45, and 52, the low-risk HPV type 6, and
a negative control. Qualitative assays were... (More) - Twenty-nine laboratories in 12 countries participated in a study to assess the performance of various human
papillomavirus (HPV) detection assays through the use of a recombinant HPV DNA standard reagent panel.
The panel was designed by a group of HPV experts, and samples were prepared and distributed by the World
Health Organization International Laboratory for Standards and Biologicals in The Netherlands. Each panel
consisted of 24 coded samples including a dilution series for HPV types 16 and 18, alone or in combination with
five other high-risk (HR) HPV types including HPV types 31, 33, 35, 45, and 52, the low-risk HPV type 6, and
a negative control. Qualitative assays were generally consistent across laboratories, and most invalid results
reflected a lack of HPV test sensitivity. The combined data sets had a proficiency for HPV 16 of 62.5% (15/24)
and for HPV 18 of 73.9% (17/23). HPV 31 was the least accurately detected by participating laboratories.
Approximately half of participating laboratories failed to detect high concentrations of HPV 31 and, to a lesser
extent, to detect HPV types 35, 52, and 6. The panel sample materials offer a source of renewable and
reproducible material that could be used in the future development of international standard reagents for
calibration of HPV DNA assays and kits. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1135939
- author
- Quint, W G V ; Pagliusi, S ; Lelie, N ; de Villiers, E M ; Wheeler, C M ; Dillner, Joakim LU and Human Papillomavirus DNA international collaborative study group., World Health Organization Human Papillomavirus DNA international collaborative study group.
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Microbiology
- volume
- 44
- issue
- 2
- pages
- 571 - 579
- publisher
- American Society for Microbiology
- external identifiers
-
- scopus:32344444715
- ISSN
- 1098-660X
- DOI
- 10.1128/JCM.44.2.571–579.2006
- language
- English
- LU publication?
- yes
- id
- 14be53a5-4c61-43b1-bbae-836aecf1f67f (old id 1135939)
- date added to LUP
- 2016-04-01 16:20:29
- date last changed
- 2022-04-30 20:35:46
@article{14be53a5-4c61-43b1-bbae-836aecf1f67f,
abstract = {{Twenty-nine laboratories in 12 countries participated in a study to assess the performance of various human<br/><br>
papillomavirus (HPV) detection assays through the use of a recombinant HPV DNA standard reagent panel.<br/><br>
The panel was designed by a group of HPV experts, and samples were prepared and distributed by the World<br/><br>
Health Organization International Laboratory for Standards and Biologicals in The Netherlands. Each panel<br/><br>
consisted of 24 coded samples including a dilution series for HPV types 16 and 18, alone or in combination with<br/><br>
five other high-risk (HR) HPV types including HPV types 31, 33, 35, 45, and 52, the low-risk HPV type 6, and<br/><br>
a negative control. Qualitative assays were generally consistent across laboratories, and most invalid results<br/><br>
reflected a lack of HPV test sensitivity. The combined data sets had a proficiency for HPV 16 of 62.5% (15/24)<br/><br>
and for HPV 18 of 73.9% (17/23). HPV 31 was the least accurately detected by participating laboratories.<br/><br>
Approximately half of participating laboratories failed to detect high concentrations of HPV 31 and, to a lesser<br/><br>
extent, to detect HPV types 35, 52, and 6. The panel sample materials offer a source of renewable and<br/><br>
reproducible material that could be used in the future development of international standard reagents for<br/><br>
calibration of HPV DNA assays and kits.}},
author = {{Quint, W G V and Pagliusi, S and Lelie, N and de Villiers, E M and Wheeler, C M and Dillner, Joakim and Human Papillomavirus DNA international collaborative study group., World Health Organization Human Papillomavirus DNA international collaborative study group.}},
issn = {{1098-660X}},
language = {{eng}},
number = {{2}},
pages = {{571--579}},
publisher = {{American Society for Microbiology}},
series = {{Journal of Clinical Microbiology}},
title = {{Results of the first World Health Organization international collaborative study of detection of Human Papillomavirus DNA.}},
url = {{http://dx.doi.org/10.1128/JCM.44.2.571–579.2006}},
doi = {{10.1128/JCM.44.2.571–579.2006}},
volume = {{44}},
year = {{2006}},
}